相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Hovione and Industrial Design Consultancy Ltd (IDC) have completed device design and established manufacturing capabilities for their lead single-use nasal dry powder device, making it available for commercial partnerships. - The platform enables pharmaceutical partners to leverage existing capsule-filling infrastructure, simplifying development while reducing costs, risks, and shortening timelines to clinic and commercialization. - The integrated solution spans API development, particle engineering, formulation manufacturing, capsule filling, and device supply, with patent protection covering the platform technology. - A multi-dose variant is currently in development to expand the platform's applicability across different therapies and dosing regimens.
- Hovione and Microinnova Engineering have formed a strategic partnership to test and develop multi-purpose, plug-and-play modular equipment for flow chemistry in pharmaceutical manufacturing. - The collaboration aims to accelerate process development and enable seamless transition from laboratory to large-scale manufacturing, ultimately reducing time to market for pharmaceutical customers. - Microinnova's modular manufacturing equipment is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production. - The partnership represents Hovione's commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in their long-term drug substance strategy.
- Hovione and Firstgene Life Sciences have established a strategic collaboration to develop a tissue-specific gene therapy targeting hepatocellular carcinoma, the most common type of liver cancer and third leading cause of cancer-related deaths worldwide. - The partnership leverages Hovione's proprietary virus-like particle platform technology, which enables highly specific delivery of genetic material to target tissues while minimizing off-target effects common in conventional gene therapies. - This collaboration represents Xlife Sciences AG's strategic entry into the gene therapy market, expanding its portfolio into high-potential therapeutic areas while addressing a significant unmet medical need for the approximately 900,000 new HCC cases diagnosed annually.
• Surf Bio has appointed Doug Hecker as Head of Technical Operations, bringing over 30 years of expertise in chemistry, manufacturing, and controls to advance their SnapShot™ platform for high-concentration biologic delivery. • Hecker's background includes commercializing Captisol® and leadership roles at Hovione and Davos Pharma, positioning him to scale manufacturing capabilities for Surf Bio's proprietary technology enabling subcutaneous administration of high-dose biologics. • The SnapShot™ platform, developed from Stanford University research, uses a proprietary polymer to create ultra-high concentration formulations of monoclonal antibodies that can be administered via standard autoinjector, addressing growing demand for convenient biologic delivery options.
